Detalles de la búsqueda
1.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 625-635, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405088
2.
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Cancer
; 126(22): 4847-4858, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32780421
3.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 175(1): 265-266, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30632020
4.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 165(3): 573-583, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28664507
5.
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
Breast Cancer Res Treat
; 161(1): 63-72, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27798749
6.
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Breast Cancer Res Treat
; 150(2): 279-88, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25721604
7.
Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group.
Cancers (Basel)
; 15(5)2023 Mar 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36900372
8.
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Clin Cancer Res
; 29(4): 805-814, 2023 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36441798
9.
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
BMC Cancer
; 11: 140, 2011 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-21496284
10.
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.
Breast Care (Basel)
; 16(1): 50-58, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33716632
11.
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Cancers (Basel)
; 13(19)2021 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34638369
12.
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.
Breast Care (Basel)
; 15(1): 82-95, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32231503
13.
ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results.
Geburtshilfe Frauenheilkd
; 80(6): 588-600, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32565549
14.
ABC4 Consensus: Assessment by a German Group of Experts.
Breast Care (Basel)
; 13(1): 48-58, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29950968
15.
4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts.
Geburtshilfe Frauenheilkd
; 78(5): 469-480, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880982
16.
The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Clin Breast Cancer
; 17(2): 100-106, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27884722
17.
Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial.
Breast Cancer
; 24(2): 319-325, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27262301
18.
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
J Clin Oncol
; 35(26): 3046-3054, 2017 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28682681
19.
Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine: Results of a prospective multi-center study at certified breast centers.
Breast
; 29: 208-12, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27344290
20.
ABC3 Consensus: Assessment by a German Group of Experts.
Breast Care (Basel)
; 11(1): 61-70, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27051399